Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
It is the first monoclonal antibody drug for use in any animal species
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
This test analyses samples in VTM directly without the need for RNA extraction step
Subscribe To Our Newsletter & Stay Updated
